Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00691483 · ClinicalTrials.gov registry record · Phase 4
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
A Phase 4 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 659
- Enrollment target
- 20
- Study locations
NCT00691483 is a Phase 4 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 659 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00691483, a Phase 4 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 659 participants
- Enrollment target
- 20
- Study locations
Study Summary
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
Conditions Studied
Interventions
- DRUG placebo
- DRUG varenicline
Study Locations (20)
Other
- Pfizer Investigational Site - Buenos Aires
- Pfizer Investigational Site - Beijing
- Pfizer Investigational Site - Guangzhou
- Pfizer Investigational Site - Brno
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Santa Ana
Pennsylvania
- Pfizer Investigational Site - Bridgeville
- Pfizer Investigational Site - Philadelphia
Arizona
- Pfizer Investigational Site - Litchfield Park
Kansas
- Pfizer Investigational Site - Overland Park
Kentucky
- Pfizer Investigational Site - Lexington
Massachusetts
- Pfizer Investigational Site - Milford
Nebraska
- Pfizer Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00691483
The ClinicalTrials.gov registry entry for NCT00691483 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 659 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (40% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00691483 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00691483 about?
NCT00691483 is a clinical study titled "Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date". The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
What is the current status of trial NCT00691483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 659 participants. The study started on 2008-09. Estimated completion is 2009-12.
What conditions does trial NCT00691483 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00691483?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT00691483?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00691483 being conducted?
This trial has 20 study locations across Arizona, California, Kansas, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.